BMRA NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Biomerica Inc · Healthcare · Medical Devices

Open interactive chart View report data Download investor PDF
Latest close 1.58 USD
-1.8% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -26.0% below the Trend Line and sits at 0.5% of its 52-week range. The latest completed week returned -1.8%, after a -9.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal; earnings are due in 36d.

Setup score 10 out of 100
Latest Close 1.58 USD 24 Jul 2026
1W Return -1.8% latest completed week
4W Return -9.4% short-term follow-through
12W Return -27.6% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.8% Latest completed week; four-week move -9.4%. Indicator stack 0/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.76% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 42 relevant articles in the latest sentiment read. Event risk 36d Next report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -26.0% below the Trend Line and sits at 0.5% of its 52-week range. The latest completed week returned -1.8%, after a -9.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1812-week average 0.24

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -9.4% over four weeks, -27.6% over 12 weeks, and -59.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-1.8%
4W-9.4%
12W-27.6%
26W-38.3%
52W-59.5%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.08Latest activity-pressure read.
Pressure change-2832.0%Four-week change in activity pressure.
Leadership-40.52Latest relative-leadership reading.
RS change0.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 May 2025 Field coverage 82% Model confidence 74%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength70/100Blend of value, momentum, and quality. Underlying universe rank 31; rank 1 is best.
Value59/100Relative valuation strength. Underlying universe rank 42; rank 1 is best.
Quality58/100Profitability and accounting quality. Underlying universe rank 43; rank 1 is best.
Momentum60/100Medium-term price momentum. Underlying universe rank 41; rank 1 is best.
Growth60/100Revenue and earnings growth. Underlying universe rank 41; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-82.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
4.3%
Gross profit retained from each unit of revenue.
Operating margin
-96.0%
Operating profit retained from revenue.
Free-cash-flow margin
-71.6%
Free cash flow generated from revenue.
Return on invested capital
-143.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-23.8%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-30.5%
Net share repurchases relative to market value.
Shareholder yield
-30.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 42 relevant articles.

7 positive · 31 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings36dNext report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-65.5%Distance below the 52-week high.
13-week volatility5.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2616 weeks finished lower.
Best week+11.2%Week of 20 Mar.
Worst week-12.7%Week of 19 Jun.
Latest week-1.8%Week of 24 Jul.

Shape of recent returns

Strong gains4
Modest gains5
Flat weeks1
Modest losses6
Sharp losses10
Recent vol5.4%13-week weekly-return volatility.
Base vol6.9%52-week weekly-return volatility.
Up/down split18/32Count of positive and negative weeks in the 52-week window.
Average skew6.0% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape11/100

Trend, activity pressure, participation, and risk combine to a 11/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.18; No reversal markers Next-Week ExpectancyNegative 39.76%

Next-week expectancy is negative with a 39.76% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors61/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 42 relevant articles.

Biomerica Inc (BMRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders50/100

No recent insider transaction evidence is stored.

 Earnings36d

Next report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20261.58 USD-1.8%2.14 USD4.30 USD-1.08-40.5228.1KOff
17 Jul 20261.61 USD-4.5%2.18 USD4.37 USD-0.98-41.7334.1KOff
10 Jul 20261.69 USD-3.4%2.20 USD4.43 USD-0.73-42.5632.7KOff
3 Jul 20261.75 USD0.0%2.23 USD4.49 USD-0.32-40.4025.0KOff
26 Jun 20261.75 USD-2.2%2.25 USD4.54 USD0.04-40.8455.8KOff
19 Jun 20261.79 USD-12.7%2.27 USD4.60 USD0.53-43.07143.0KOff
12 Jun 20262.05 USD-3.3%2.29 USD4.66 USD0.85-34.1398.2KOff
5 Jun 20262.12 USD-11.2%2.30 USD4.73 USD1.05-31.3097.7KOff
29 May 20262.39 USD-4.1%2.31 USD4.80 USD1.10-27.2090.2KOff
22 May 20262.49 USD6.4%2.32 USD4.85 USD0.85-22.7757.2KOff
15 May 20262.34 USD5.4%2.34 USD4.91 USD0.52-27.37147.6KOff
8 May 20262.22 USD1.4%2.36 USD4.97 USD0.14-32.38104.3KOff
1 May 20262.19 USD2.3%2.38 USD5.02 USD-0.16-30.8521.4KOff
24 Apr 20262.14 USD-1.8%2.40 USD5.08 USD-0.30-32.5335.1KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.